A Review of Results from Clinical Trials Based on Co-Variants of the R-CHOP Regimen in Untreated Patients with Diffuse Large B-cell Lymphoma
نویسندگان
چکیده
Summary Since 2000, new drugs for treating lymphoproliferative diseases have been introduced in haematology, and their initial indications gradually expanded. Some of the so-called „target molecules“ shown good efficacy when some malignant non-Hodgkin lymphomas. The possibility achieving therapeutic disease control indolent lymphomas using with a different mechanism action from that cytostatics has logically raised question change management other diseases. 2010, clinical trials initiated untreated patients aggressive non-Hodgkin‘s lymphoma - diffuse large B-cell as primary target. key aim most to compare „gold standard“ rituximab, cyclophosphamide, doxorubicin, oncovin, prednisolone (R- CHOP) versus its derivatives. review discusses results completed published on Internet. These covered covariants R-CHOP regimen used first-line treatment lymphoma. also includes registered Bulgaria last ten years but indication at present. five which obinotuzumab, venetoclax, lenalidomide, bortezomib, ibrutinib were are presented.
منابع مشابه
ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
Activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL), the major constituent of nongerminal center B-cell-like (non-GCB) DLBCL, is associated with poorer survival outcomes than GCB-type DLBCL. In Phase II studies, lenalidomide combined with R-CHOP (R(2)-CHOP) improved outcomes relative to historical R-CHOP in newly diagnosed DLBCL, particularly in non-GCB cases. ROBUST (CC-5013-DLC-...
متن کاملResults of CHOP chemotherapy for diffuse large B-cell lymphoma.
Patients with diffuse large B-cell lymphoma treated in a University Hospital were studied from 1990 to 2001. Two treatment regimens were used: ProMACE-CytaBOM and then, from November 1996 on, the CHOP regimen. Complete remission (CR), disease-free survival (DFS), and overall survival (OS) rates were determined. Primary refractory patients and relapsed patients were also assessed. A total of 111...
متن کاملR-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.
Vascular endothelial growth factor is involved in lymphoma growth, suggesting a potential role for anti-vascular endothelial growth factor therapies in hematologic malignancies. In this phase III study, patients with CD20-positive diffuse large B-cell lymphoma were randomized to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone plus either placebo (R-CHOP) or bevacizumab (RA...
متن کاملMeasurement of pyruvate dehydrogenase enzyme in patients with diffuse large B-cell lymphoma relapse
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL), which is the most common type of lymphoma. NHL comprises a group of clinically and biologically diverse diseases, which range from indolent to aggressive clinical courses. Despite treatment advances in the last three decades with the use of combination immunotherapy, a significant fraction...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Biomedical and Clinical Research
سال: 2021
ISSN: ['1313-9053', '1313-6917']
DOI: https://doi.org/10.2478/jbcr-2021-0016